Remicade plus thiopurine for Crohn’s yields better outcomes in first 6 months

Remicade plus optimized thiopurine was superior in patients with Crohn’s disease compared with infliximab monotherapy for response initiation, durability and clinical outcomes in the first 6 months after induction, according to recently published study results.“Thereafter combination therapy yielded no clinical advantage, supporting consideration of thiopurine withdrawal on a casebycase basis,” Raphael P. Luber, MD, from the department of gastroenterology at The Alfred Hospital, Melbourne, Victoria, Australia, and colleagues wrote.Luber and colleagues retrospectivelyRead More

Share on facebook
Share on twitter
Share on linkedin